Guanfacine hydrochlorideMeSH concept

https://www.ema.europa.eu/en/medicines/human/EPAR/paxneury
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
guanfacine
guanfacine
attention deficit disorder with hyperactivity
child
adolescent
Attention deficit disorder of childhood without mention of hyperactivity
drugs, generic
continuity of patient care
administration, oral
tablets
Product containing only guanfacine in oral dose form (medicinal product form)
guanfacine hydrochloride
guanfacine hydrochloride
Delayed-Action preparations
Product containing precisely guanfacine (as guanfacine hydrochloride) 1 milligram/1 each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 2 milligram/1 each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 3 milligram/1 each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 4 milligram/1 each prolonged-release oral tablet (clinical drug)
drug monitoring
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
receptor, adrenergic, alpha-2A
Alpha-2 adrenergic receptor agonist (disposition)

---